Dr. Reddy’s introduces generic Plaquenil tablets
Dr. Reddy’s Laboratories has received the OK from the Food and Drug Administration for a generic version of Concordia’s Plaquenil (hydroxychloroquine sulfate tablets) in a 200-mg dosage strength.
The product is indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale and P. vivax; the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported; the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and the treatment of acute and chronic rheumatoid arthritis in adults.
Dr. Reddy’s hydroxychloroquine sulfate tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
The product’s market size was approximately $215 million for the 12 months ended May 2018, according to IQVIA data.
The product is indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale and P. vivax; the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported; the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults; and the treatment of acute and chronic rheumatoid arthritis in adults.
Dr. Reddy’s hydroxychloroquine sulfate tablets are available in 200 mg tablets in the bottle count sizes of 100 and 500.
The product’s market size was approximately $215 million for the 12 months ended May 2018, according to IQVIA data.